HealthcareServices

Nasal Spray Influenza Vaccine Industry Poised for Rapid Growth, Forecast to Touch $2.67 Billion by 2030 at 12.7% CAGR

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the nasal spray influenza vaccine market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Nasal Spray Influenza Vaccine Market reach by 2030 starting from 2026 levels?

The nasal spray influenza vaccine market size has expanded considerably in recent years. It is projected to increase from $1.48 billion in 2025 to $1.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.7%. The growth observed in the past can be ascribed to a rise in flu vaccination awareness, the dependence on traditional injection-based flu vaccines, government-sponsored influenza immunization initiatives, occurrences of seasonal flu outbreaks, and the restricted availability of needle-free options.

The nasal spray influenza vaccine market is projected to experience substantial growth over the next few years. It is expected to expand to $2.68 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.7%. This anticipated growth can be attributed to several factors, including an increasing preference for needle-free delivery systems, the expansion of immunization programs targeting both pediatric and geriatric populations, rising investments in nasal vaccine research and development, the creation of advanced attenuated vaccine formulations, and global initiatives aimed at increasing vaccination coverage. Prominent trends throughout this forecast period include the growing adoption of needle-free vaccination methods, a rising demand for flu vaccines designed with children in mind, the expanding utilization of quadrivalent live attenuated vaccines, intensified seasonal flu prevention campaigns, and the ongoing development of both multi-dose and single-dose nasal formulations.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp

Which Drivers Are Influencing Long-Term Growth In The Nasal Spray Influenza Vaccine Market?

The rising occurrence of influenza is anticipated to fuel the expansion of the nasal spray influenza vaccine market. Influenza is defined as a highly communicable viral disease predominantly impacting the respiratory system, leading to symptoms like fever, coughing, sore throat, body aches, and tiredness. This growing prevalence largely stems from the influenza virus’s frequent genetic mutations, which allow it to bypass current immunity and disseminate quickly within populations. The nasal spray influenza vaccine offers protection by introducing a weakened version of the virus directly into the nasal passages, thereby eliciting an immune reaction at the typical entry point for the virus. For example, in September 2024, preliminary data from the Centers for Disease Control and Prevention (CDC), the US national health protection agency, for the 2023–2024 U.S. influenza season indicated between 34 million and 75 million symptomatic illnesses, 15 million to 33 million medical visits, 380,000 to 900,000 hospitalizations, and 17,000 to 100,000 deaths. Notably, older adults (=65 years) comprised 51% of hospitalizations and 68% of deaths. Consequently, the rising incidence of influenza is propelling the expansion of the nasal spray influenza vaccine market.

How Is The Nasal Spray Influenza Vaccine Market Divided Into Segments?

The nasal spray influenza vaccine market covered in this report is segmented –

1) By Type: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine

2) By Administration Method: Single-Dose Administration, Multi-Dose Administration

3) By Age Group: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Online Stores, Other Distribution Channels

5) By End User: Healthcare Providers, Individuals, Government Health Departments, Pharmaceutical Companies

Subsegments:

1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV), Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)

2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine, Split Virus Inactivated Vaccine, Subunit Inactivated Vaccine, Adjuvanted Inactivated Vaccine, High-Dose Inactivated Vaccine

Which Trends Are Shaping Activity Within The Nasal Spray Influenza Vaccine Market?

Leading companies active in the nasal spray influenza vaccine market are prioritizing the development of innovative formulations, specifically live attenuated influenza vaccine, to enhance immune response and boost patient compliance. A live attenuated influenza vaccine (LAIV) is crafted from live, weakened influenza viruses and works by prompting the immune system to produce antibodies, thereby preventing influenza without inducing the disease. It also delivers a more comprehensive immune response through both local and systemic immunity, significantly improving the body’s capacity to ward off subsequent flu infections. For instance, in September 2024, AstraZeneca Plc, a UK-based pharmaceutical industry company, obtained approval from the U.S. Food and Drug Administration (FDA) for FluMist, a live attenuated influenza vaccine (LAIV). This approval allows for its self-administration by adults up to 49 years of age or administration by caregivers to children aged 2 to 17 years, making it the premier and sole influenza vaccine approved for self- or caregiver-administration in the United States. This endorsement was founded on extensive usability studies that confirmed individuals’ capability to accurately self-administer the vaccine, with 100% of participants delivering a full dose as directed.

Which Key Players Are Driving Competition In The Nasal Spray Influenza Vaccine Market?

Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, GSK plc, FluGen Inc., BioDiem Ltd, Codagenix Inc, Altimmune Inc, AstraZeneca PLC, MedImmune LLC, BCHT Biotechnology Co Ltd, Serum Institute of India Pvt Ltd, Vivaldi Biosciences, Vaccitech, Blue Water Vaccines, VaxInnate, INOVIO Pharmaceuticals, Cipla Ltd, Beijing Wantai Biological Pharmacy Enterprise Co Ltd, Bharat Biotech, Novavax Inc, BioNTech SE, Transgene SA, BiondVax Pharmaceuticals Ltd, Adimmune Corporation, Teva Pharmaceutical Industries Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report

Which Region Currently Holds The Largest Share Of The Nasal Spray Influenza Vaccine Market?

North America was the largest region in the nasal spray influenza vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Nasal Spray Influenza Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24326&type=smp

Browse Through More Reports Similar to the Global Nasal Spray Influenza Vaccine Market 2026, By The Business Research Company

Influenza Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-diagnostic-global-market-report

Influenza Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Respiratory Disease Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795